Ventyx Biosciences, Inc.

VTYX - CIK 0001851194

Market cap$1.00 B

Rank#2638

SEC filings495

Ventyx Biosciences, Inc. trades as VTYX and has a market capitalization of $1.00 B, making it the #2638 largest US-listed company by market value. This page tracks Ventyx Biosciences, Inc. through 495 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Net income (latest FY)-$135.12MFY 2024

Operating cash flow (latest FY)-$130.87MFY 2024

Total assets (latest FY)$276.56MFY 2024

Financial performance

VTYX annual net incomeView details

VTYX operating cash flowView details

Key statistics

Market cap: $1.00 B
Share price (derived)market cap / shares outstanding: $14.08
EPS (diluted)FY 2024: $-1.97
Shares outstandingas of 2025-11-03: 0.07B
Total equityas of 2025-09-30: $191.36M
Return on equity: -70.6%
Cash & equivalentsas of 2025-09-30: $31.97M
Current ratioas of 2025-09-30: 17.86

Latest filings

Filing	Type	Filed
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-14
SCHEDULE 13G/A	-	2026-05-14
15-12G	-	2026-03-16
EFFECT	-	2026-03-06
EFFECT	-	2026-03-06
SCHEDULE 13D/A	-	2026-03-05
Insider trade	4	2026-03-04

Browse the full filing history (495 filings)

Recent press releases

Select Language2025-09-14
Lilly and our partners use cookies to operate our site that are always on and for other optional analytics, personalization, and marketing. Accept or Reject optional cookies. To modify your choice and for more details, see Cookie Settings. For more information see our Privacy Statement.
Lilly Australia And New Zealand Launch Enable Resource Group To Foster Inclusive Culture2024-12-02
Lilly and our partners use cookies to operate our site that are always on and for other optional analytics, personalization, and marketing. Accept or Reject optional cookies. To modify your choice and for more details, see Cookie Settings. For more information see our Privacy Statement.
Select Language2024-10-09
Lilly and our partners use cookies to operate our site that are always on and for other optional analytics, personalization, and marketing. Accept or Reject optional cookies. To modify your choice and for more details, see Cookie Settings. For more information see our Privacy Statement.
Select Language2024-05-31
Lilly and our partners use cookies to operate our site that are always on and for other optional analytics, personalization, and marketing. Accept or Reject optional cookies. To modify your choice and for more details, see Cookie Settings. For more information see our Privacy Statement.

Similar companies

The largest companies sharing Ventyx Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T VTYX vs LLY

JNJJohnson & Johnson$573.98 B VTYX vs JNJ

ABBVAbbVie Inc.$399.47 B VTYX vs ABBV

MRKMerck & Co., Inc.$293.16 B VTYX vs MRK

AZNAstraZeneca PLC$286.27 B VTYX vs AZN

Frequently asked questions

What is Ventyx Biosciences, Inc.'s market cap?

Ventyx Biosciences, Inc. (VTYX) has a market capitalization of $1.00 B as of 2026-05-29, ranking #2638 among US-listed companies.

Is Ventyx Biosciences, Inc. profitable?

In its latest fiscal year Ventyx Biosciences, Inc. reported a net loss of $135.12M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.